UK Rare Disease Drug Review Reform Urged As Spinraza Finally Gets NICE OK
Executive Summary
It has taken 17 months of negotiations but soon 600-1,200 people in the UK may be able to get Biogen's spinal muscular atrophy therapy now that an access agreement has been inked.
You may also be interested in...
A First For England's NICE - Interim Review Of Spinraza Access Agreement Gets Under Way
NICE will review new data in deciding whether to OK the use of Spinraza in non-ambulant SMA type III patients.
Concerns Emerge Over England’s Desire For Even Lower Drug Prices
With the emphasis on getting lower prices even for cost-effective drugs, England’s proposed commercial framework may be sending a negative signal to global companies.
NHS England Offers ‘Improved’ Orkambi Deal, But Vertex Lukewarm
The NHS in England says it has made a “revised and improved” offer to Vertex to make Orkambi available, but the company is not impressed and says its attitude to the negotiations has been mischaracterized.